首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1698272

鴉片類藥物市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

Opioid Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

出版日期: 2025年02月24日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球鴉片類藥物市場價值為 250 億美元，預計 2025 年至 2034 年期間的複合年成長率為 1.8%，這主要得益於癌症疼痛、關節炎、纖維肌痛和術後疼痛等慢性疼痛疾病盛行率的上升。隨著人口老化加劇以及需要長期疼痛管理的患者數量不斷增加，對鴉片類藥物的需求持續上升。

鴉片類藥物產業正在經歷重大轉型，受到監管變化和不斷發展的醫療保健政策的影響。政府和醫療保健提供者正在平衡有效疼痛管理的需求和對鴉片類藥物依賴的擔憂。雖然各個地區都對鴉片類藥物處方實施了嚴格的監管，但具有防濫用特性的鴉片類藥物配方的創新正在幫助維持市場成長。此外，製藥公司正在投資研究開發更安全的鴉片類藥物替代品，同時保持其緩解疼痛的功效。緩釋製劑等藥物傳遞系統的進步進一步促進了市場擴張。隨著醫療保健提供者採用個人化的疼痛管理方法，鴉片類藥物市場預計將繼續成為製藥業的重要領域。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	250億美元
預測值	296億美元
複合年成長率	1.8%

市場按藥物類型分類，包括羥可酮、氫可酮、嗎啡、芬太尼、曲馬多和其他鴉片類藥物。羥可酮繼續佔據市場主導地位，2023 年的市值為 87 億美元，預計到 2034 年將達到 109 億美元。羥可酮廣泛用於治療中度至重度疼痛，包括術後疼痛和損傷相關疾病，這對其維持市場領先地位起著關鍵作用。它在癌症疼痛管理中的顯著應用，特別是對於化療患者，進一步鞏固了它的重要性。隨著對有效緩解疼痛解決方案的需求不斷成長，羥可酮仍然是全球治療方案的重要組成部分。

疼痛管理仍然是最大的應用領域，到 2024 年將佔據 74.3% 的市場。鴉片類藥物廣泛用於治療慢性和重症患者的疼痛。透過與大腦、脊髓和其他部位的鴉片類受體結合，這些藥物可以阻斷疼痛訊號，為手術後恢復、接受癌症治療或治療關節炎等退化性疾病的患者提供必要的緩解。疼痛管理領域對鴉片類藥物的持續需求確保了該領域在預測期內將保持其市場主導地位。

2024 年美國鴉片類藥物市場價值為 104 億美元，預計未來十年的複合年成長率為 1.9%。關節炎、癌症和術後恢復等疾病的發生率不斷上升，推動了對鴉片類藥物疼痛管理解決方案的需求。美國擁有完善的醫療保健基礎設施和廣泛的鴉片類藥物使用，這對市場成長產生了重大影響。隨著醫療保健提供者不斷尋求有效的疼痛緩解解決方案，該國仍然是整個鴉片類藥物市場擴張的主要貢獻者。隨著監管框架的發展和新的疼痛管理策略的出現，鴉片類藥物市場預計將在美國和其他地區保持穩定成長。

產業生態系統分析
產業衝擊力
- 成長動力
  - 慢性疼痛發生率上升
  - 政府支持政策不斷增加
  - 鴉片類藥物製劑的進展
  - 全球外科手術日益增多
- 產業陷阱與挑戰
  - 嚴格的監管要求
  - 成癮和濫用問題日益嚴重
成長潛力分析
管道分析
監管格局
波特的分析
PESTEL 分析

第4章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第5章：市場估計與預測：按藥物類型，2021 年至 2034 年

主要趨勢
羥可酮
氫可酮
嗎啡
芬太尼
曲馬多
其他藥物類型

第6章：市場估計與預測：按應用，2021 年至 2034 年

主要趨勢
疼痛管理
麻醉
止咳
其他應用

第7章：市場估計與預測：依管理路線，2021 年至 2034 年

主要趨勢
口服
注射劑
經皮
其他給藥途徑

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第10章：公司簡介

Allergan
Amneal Pharmaceuticals
AstraZeneca
Camurus AB
Grunenthal
Hikma Pharmaceuticals
Indivior
Mallinckrodt Pharmaceuticals
Pfizer
Purdue Pharma
Rusan Pharma
Sun Pharmaceutical
Teva Pharmaceuticals

簡介目錄

Product Code: 13222

The Global Opioid Market was valued at USD 25 billion in 2024 and is projected to grow at a CAGR of 1.8% between 2025 and 2034, driven by a rising prevalence of chronic pain conditions such as cancer pain, arthritis, fibromyalgia, and post-surgical pain. With an increasing aging population and a growing number of patients requiring long-term pain management, demand for opioids continues to rise.

The opioid industry is undergoing significant transformation, shaped by both regulatory shifts and evolving healthcare policies. Governments and healthcare providers are balancing the need for effective pain management with concerns about opioid dependency. While strict regulations on opioid prescriptions have been implemented in various regions, innovations in opioid formulations with abuse-deterrent properties are helping sustain market growth. Additionally, pharmaceutical companies are investing in research to develop safer opioid alternatives while maintaining their efficacy in pain relief. Advancements in drug delivery systems, such as extended-release formulations, are further contributing to market expansion. As healthcare providers adopt personalized pain management approaches, the opioid market is expected to remain a crucial segment within the pharmaceutical industry.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$25 Billion
Forecast Value	$29.6 Billion
CAGR	1.8%

The market is categorized by drug type, including oxycodone, hydrocodone, morphine, fentanyl, tramadol, and other opioids. Oxycodone continues to hold a dominant market position, generating USD 8.7 billion in 2023 and is projected to reach USD 10.9 billion by 2034. Oxycodone's widespread use in treating moderate to severe pain, including post-surgical pain and injury-related conditions, plays a key role in its sustained market leadership. Its significant application in cancer pain management, particularly for chemotherapy patients, further solidifies its prominence. As demand for effective pain relief solutions grows, oxycodone remains an essential component of treatment protocols worldwide.

Pain management remains the largest application segment, accounting for a 74.3% market share in 2024. Opioids are extensively used for managing pain in patients suffering from chronic and intense conditions. By binding to opioid receptors in the brain, spinal cord, and other areas, these medications block pain signals, providing essential relief for patients recovering from surgery, undergoing cancer treatments, or managing degenerative diseases like arthritis. This consistent demand for opioids in pain management ensures that the segment will maintain its market dominance over the forecast period.

The U.S. Opioid Market was valued at USD 10.4 billion in 2024 and is projected to grow at a CAGR of 1.9% over the next decade. The increasing prevalence of conditions such as arthritis, cancer, and post-surgical recovery fuels the demand for opioid-based pain management solutions. The U.S. benefits from a well-established healthcare infrastructure and widespread opioid usage, which significantly influences market growth. With healthcare providers continuously seeking effective pain relief solutions, the country remains a key contributor to overall opioid market expansion. As regulatory frameworks evolve and new pain management strategies emerge, the opioid market is expected to sustain steady growth in the U.S. and beyond.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of chronic pain condition
  - 3.2.1.2 Growing supportive government policies
  - 3.2.1.3 Advancements in opioid-based drug formulations
  - 3.2.1.4 Growing surgical procedures globally
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Rising addiction and abuse concerns
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Oxycodone
5.3 Hydrocodone
5.4 Morphine
5.5 Fentanyl
5.6 Tramadol
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Pain management
6.3 Anesthesia
6.4 Cough suppression
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectables
7.4 Transdermal
7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE